Skip to search formSkip to main contentSkip to account menu

SR1664

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARγ; a Model for Ligand-Dependent Antagonism.
2017
2017
Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro
Thiazolidinediones (TZD) function as potent anti-diabetic drugs through their direct action on the nuclear receptor peroxisome… 
2016
2016
Mechanistic elucidation guided by covalent inhibitors for the development of anti-diabetic PPARγ ligands† †Electronic supplementary information (ESI) available: Supplementary figures and tables…
We revealed the X-ray structure of PPARγ co-crystallized with SR1664 bound to the alternate binding site of PPARγ and confirmed… 
Highly Cited
2015
Highly Cited
2015
Pharmacological Repression of PPARγ Promotes Osteogenesis
The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the master regulator of adipogenesis and the… 
2015
2015
Flightless-1, a novel transcriptional modulator of PPARγ through competing with RXRα.
2015
2015
PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.
Review
2014
Review
2014
Revisiting PPARγ as a target for the treatment of metabolic disorders
As the prevalence of obesity has increased explosively over the last several decades, associated metabolic disorders, including… 
Highly Cited
2014
Highly Cited
2014
A Novel Non-agonist Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand UHC1 Blocks PPARγ Phosphorylation by Cyclin-dependent Kinase 5 (CDK5) and Improves Insulin Sensitivity*
Background: PPARγ ligands can be used in numerous metabolic syndromes. Results: A novel non-agonist PPARγ ligand, UHC1 exhibited… 
Highly Cited
2011
Highly Cited
2011
Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation
PPARγ is the functioning receptor for the thiazolidinedione (TZD) class of antidiabetes drugs including rosiglitazone and… 
2011
2011
Diabetes: Safer PPARγ-targeted drugs on the horizon?
Thiazolidinediones (TZDs), which are agonists of the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ), are… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)